Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Pulmonary Hypertension
Interventions
TNX-103, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
40
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 32 more
Conditions
Heart Failure, Systolic
Interventions
Sacubitril/Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Non-obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten, Placebo
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
32
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 28 more
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
YAP101 (AAV9-Sav-shRNA)
Combination Product
Lead sponsor
Medley Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncopation, Syncope, Ischemic Cardiovascular Disease, STEMI, STEMI (ST Elevation MI), Atrial Fibrillation (AF), Atrial Enlargement, LVF, Conduction Defect, Conduction Abnormalities, Heart Block, Valvular Diseases, Cardiac Output, Low, Stroke Volume, Stroke Volume Variation, Hyperkalemia, Hypercalcemia, Hypocalcemia, LV Dysfunction, QT Prolongation, Sudden Cardiac Death Due to Cardiac Arrhythmia, Ventricular Arrhythmia, Pacing, Pacing Induced Dyssynchrony, Silent Ischemia, Pericarditis, Sleep Related Breathing Disorder, RSA, Apnea, Obstructive, Cardiac Output Measurement, Respiratory Impedance, CRT And/or ICD, Infarction, Cardiomyopathies, Primary, Hypertrophy
Interventions
SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C, SUBPROTOCOL D, SUBPROTOCOL E, SUBPROTOCOL F, SUBPROTOCOL G, SUBPROTOCOL H
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Melbourne, Florida
Conditions
Idiopathic Dilated Cardiomyopathy
Interventions
Carvedilol, Metoprolol succinate, Metoprolol succinate + doxazosin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
2
States / cities
Denver, Colorado • Salt Lake City, Utah
Conditions
Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
Interventions
15-minutes of sitting during COR ECG Acquistion
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Orange, California • Pasadena, California • Detroit, Michigan + 5 more
Conditions
Heart Failure, Congestive, Dyspnea, Pulmonary Edema
Interventions
Nesiritide
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Current or Recent History of Atrial Fibrillation
Interventions
bucindolol hydrochloride, metoprolol succinate, Placebo oral capsule
Drug · Other
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
48
States / cities
Anchorage, Alaska • Phoenix, Arizona • East Palo Alto, California + 43 more
Conditions
Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
Interventions
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
Device
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
105
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more
Conditions
Ventricular Fibrillation, Ventricular Tachycardia, Low Cardiac Output
Interventions
EMBLEM S-ICD System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
21 Years and older
Enrollment
1,173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 62 more
Recruiting Phase 2 Interventional

The CARDIOPROTECT Trial

NCT07654426
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions
Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Heart Failure, Acute Heart Failure
Interventions
Finerenone, Placebo
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years and older
Enrollment
5,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
80
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 70 more
Completed Not applicable Interventional Results available

Optimize RV Follow-up Selective Site Pacing Clinical Trial

NCT00949715
Conditions
Cardiac Pacing, Right Ventricular Pacing, Left Ventricular Ejection Fraction
Interventions
Medtronic or Vitatron Dual-Chamber Pacemaker, Medtronic SelectSecure 3830 Lead
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Des Moines, Iowa • Silver Spring, Maryland • Southfield, Michigan + 7 more
Conditions
Heart Failure
Interventions
vicadrostat, empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
91
States / cities
Beverly Hills, California • Covina, California • Encinitas, California + 77 more
Conditions
Diabetes Mellitus, Heart Failure
Interventions
Tc99m-Maraciclatide
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Heart Failure With Preserved Ejection Fraction, Diastolic Heart Failure
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Carcinoma, Renal Cell
Interventions
Sorafenib (Nexavar, BAY43-9006)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Maywood, Illinois + 4 more
Completed Not applicable Interventional Results available

FAST (Fluid Accumulation Status Trial)

NCT00289276
Conditions
Congestive Heart Failure, Cardiomyopathy, Dyspnea, Pulmonary Edema, Heart Diseases
Interventions
Fluid Status Monitoring (OptiVol™)
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
12
States / cities
Anchorage, Alaska • Atlantis, Florida • Fort Wayne, Indiana + 9 more
Enrolling by invitation No phase listed Observational

Federated Learning for Point-of-Care Cardiac Ultrasound

NCT07800962
Conditions
Ventricular Dysfunction, Left, Ventricular Function, Left, Echocardiography, Ultrasonography, Point-of-Care Systems, Heart Function Tests, Stroke Volume, Federated Learning, Machine Learning, Artificial Intelligence (AI), Deep Learning, Neural Networks, Computer, Image Interpretation, Computer-Assisted, Diagnosis, Computer-Assisted, Sensitivity and Specificity, ROC Curve
Interventions
Focused Cardiac Point-of-Care Ultrasonography, FL-POCUS Federated Machine-Learning Analysis System
Diagnostic Test · Device
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
1
States / cities
New York, New York
Active, not recruiting Not applicable Interventional

Assessment of Combined CCM and ICD Device in HFrEF

NCT05855135
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy, Non-ischemic Cardiomyopathy, Ischemic Cardiomyopathy, Sudden Cardiac Arrest, Arrhythmias, Cardiac, Ventricular Tachycardia, Ventricular Fibrillation
Interventions
OPTIMIZER® Integra CCM-D System (Treatment Arm)
Device
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
59
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 40 more
Conditions
3D Transesophageal and Transthoracic Echocardiogram
Interventions
transesophageal echocardiography (TEE), thermodilution, transthoracic echocardiography (TTE)
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Anemia
Interventions
Erythropoietin alpha, Placebo
Drug
Lead sponsor
Mathew S. Maurer
Other
Eligibility
55 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Heart Failure
Interventions
Placebo, Omecamtiv mecarbil
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Mobile, Alabama • Inglewood, California • La Jolla, California + 38 more